Pharmalot… Pharmalittle… The Weekend Nears
Make a commentBy Ed Silverman // June 17th, 2011 // 7:15 am
And so, another working week is about to draw to a close. This is, of course, our signal to daydream about weekend plans. For now, we intend to do some reading, catch up with our short people and promenade with the official Pharmalot mascots. And you? Anything special? Perhaps a drive in the country? A chance to meet with friends? Or maybe balance your checkbook and show the indebted nations how it’s done? Whatever your fancy, have a great time. Oh, and say ‘hi’ to Dad…
FDA Reviewers Say Novartis Gout Drug Data Is Complicated (Reuters)
Roche Faces Significant Hurdles For Avastin Breast Cancer Indication (Financial Times)
UK Officials Say Pfizer Doing ‘Too Little’ As Plant Closes (BBC)
FDA Approves Expanded Use Of Celgene Lymphoma Drug (Reuters)
AstraZeneca Increases Investment In Russia (Pharma Times)
Pfizer And Bristol Bloodthinner Data Will Make The Difference (Reuters)
CMS Leaves Coverage Intact For Amgen And J&J Anemia Meds (Bloomberg News)
UK’S NICE Rejects J&J Appeal Over Backing For Celgene Drug (Bloomberg News)
NICE Draft Advice Backs Glaxo And Valeant Epilepsy Drug (Reuters)
Contract Pharmaceuticals Lays Off More Workers (Buffalo Business First)
EDITOR’S NOTE: Please check this post for updates throughout the morning
pix thx to carrera911e on flickr creative commons
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
AstraZeneca, Avastin, Bloodthinner, Bristol Myers Squibb, Celgene, Epilepsy, FDA, Genentech, GlaxoSmithKline, JJ, Johnson & Johnson, Lymphoma, NICE, Pfizer, Roche, Russia, Thalidomid, UK, Valeant Pharmaceuticals